Antibiotic Incentives: A Warm-up for Big Stakes Fight over Follow-on Biologics
This article was originally published in RPM Report
Executive Summary
Drug development incentives for neglected diseases, antibiotics and enantiomers in the Senate's drug safety/user fee bill do not appear to create niches for blockbuster commercial products, but they are not insignificant. They are important as much as markers that Congress, despite the new Democratic majority, is still open to certain types of incentives for the drug industry.
You may also be interested in...
Antibiotic Incentive Bill Reintroduced: Industry Hopes for 2012 Enactment
The bill focuses on particularly virulent, resistant pathogens and also includes priority review designations and review of FDA guidelines.
Antibiotic Assistance
The drug safety/user fee bill working its way through Congress has some surprising benefits for antibiotic drug developers, and a voucher scheme to let companies developing drugs for tropical diseases earn the right to faster FDA reviews for more commercially attractive products.
Antibiotic Assistance
The drug safety/user fee bill working its way through Congress has some surprising benefits for antibiotic drug developers, and a voucher scheme to let companies developing drugs for tropical diseases earn the right to faster FDA reviews for more commercially attractive products.